Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Daiichi Sankyo Company, Limited stock logo
DSNKY
Daiichi Sankyo
$25.02
+1.8%
$24.96
$22.47
$42.48
$47.75BN/A245,821 shs252,390 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$822.99
+0.2%
$842.43
$711.40
$972.53
$781.34B0.343.14 million shs258,836 shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$88.90
+1.5%
$92.09
$81.04
$134.63
$224.15B0.3510.27 million shs1.26 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$69.91
-0.4%
$82.52
$69.56
$148.15
$313.39B0.425.47 million shs1.06 million shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Daiichi Sankyo Company, Limited stock logo
DSNKY
Daiichi Sankyo
+1.83%+4.60%+8.69%-10.39%-23.60%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-0.57%-2.51%-8.90%+4.98%+5.58%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-0.52%-7.52%-4.26%-12.14%-33.51%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-2.18%-10.87%-22.83%-19.68%-45.19%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Daiichi Sankyo Company, Limited stock logo
DSNKY
Daiichi Sankyo
N/AN/AN/AN/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.8218 of 5 stars
2.45.03.34.03.42.51.9
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
5 of 5 stars
4.35.04.23.92.73.33.8
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
4.8113 of 5 stars
4.45.01.70.02.40.04.4
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Daiichi Sankyo Company, Limited stock logo
DSNKY
Daiichi Sankyo
0.00
N/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.85
Moderate Buy$1,009.7222.69% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.65
Moderate Buy$117.1231.74% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.80
Moderate Buy$145.25107.78% Upside

Current Analyst Ratings Breakdown

Latest LLY, NVO, DSNKY, and MRK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/13/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Kepler Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
3/6/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$1,146.00
3/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$970.00 ➝ $1,100.00
3/3/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
2/18/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$128.00 ➝ $105.00
2/12/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$122.00 ➝ $115.00
2/12/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageEqual Weight
2/10/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
TD Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$121.00 ➝ $100.00
2/10/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$121.00 ➝ $100.00
2/5/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$118.00 ➝ $112.00
2/5/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Perform ➝ Market Perform$105.00 ➝ $96.00
(Data available from 3/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Daiichi Sankyo Company, Limited stock logo
DSNKY
Daiichi Sankyo
$11.09B4.30N/AN/A$5.62 per share4.45
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B17.32$13.42 per share61.34$15.05 per share54.68
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$64.17B3.50$3.08 per share28.82$14.85 per share5.99
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$290.40B1.08$3.24 per share21.57$4.64 per share15.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Daiichi Sankyo Company, Limited stock logo
DSNKY
Daiichi Sankyo
$1.39B$0.8629.0922.951.7213.62%14.53%7.07%4/23/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$11.7170.3726.451.4023.51%85.24%16.19%5/1/2025 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$17.12B$6.7313.198.980.7726.67%45.35%17.36%4/24/2025 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$14.64B$3.2921.2315.000.9034.81%84.68%26.29%5/7/2025 (Estimated)

Latest LLY, NVO, DSNKY, and MRK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/24/2025N/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.16N/AN/AN/A$15.59 billionN/A
2/6/2025Q4 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.45$5.32-$0.13$4.88$13.42 billionN/A
2/5/2025Q4 2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.88$0.91+$0.03$0.91N/AN/A
2/4/2025Q4 2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$1.85$1.72-$0.13$1.48$15.51 billion$15.62 billion
1/31/2025N/A
Daiichi Sankyo Company, Limited stock logo
DSNKY
Daiichi Sankyo
N/A$0.22N/A$0.22N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Daiichi Sankyo Company, Limited stock logo
DSNKY
Daiichi Sankyo
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.73%+15.21%51.24%11 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.243.64%+5.73%48.14%14 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.572.25%+25.26%47.72%N/A

Latest LLY, NVO, DSNKY, and MRK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/5/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
semi-annual$0.78741.2%3/31/20253/31/20254/8/2025
1/28/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.813.32%3/17/20253/17/20254/7/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Daiichi Sankyo Company, Limited stock logo
DSNKY
Daiichi Sankyo
0.06
2.77
2.11
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.00
1.15
0.97
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.79
1.36
1.15
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.62
0.74
0.55

Institutional Ownership

CompanyInstitutional Ownership
Daiichi Sankyo Company, Limited stock logo
DSNKY
Daiichi Sankyo
N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%

Insider Ownership

CompanyInsider Ownership
Daiichi Sankyo Company, Limited stock logo
DSNKY
Daiichi Sankyo
N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.09%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
Daiichi Sankyo Company, Limited stock logo
DSNKY
Daiichi Sankyo
17,4351.91 billionN/ANot Optionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000948.17 million948.08 millionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
69,0002.53 billion2.53 billionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
54,4004.49 billion4.48 billionOptionable

Recent News About These Companies

Why Novo Nordisk Stock Dipped on Thursday
Novo Nordisk A/S stock logo
Top Growth Stocks To Follow Now - March 27th
Resolutions from the Annual General Meeting of Novo Nordisk A/S
1 Growth Stock Down 40% to Buy and Hold Forever
Brokerages Set Novo Nordisk A/S (NYSE:NVO) Price Target at $145.25

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Daiichi Sankyo stock logo

Daiichi Sankyo OTCMKTS:DSNKY

$25.02 +0.45 (+1.83%)
As of 03/27/2025 03:59 PM Eastern

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$822.98 +1.32 (+0.16%)
As of 10:24 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$88.90 +1.30 (+1.48%)
As of 10:24 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$69.90 -0.26 (-0.36%)
As of 10:24 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.